National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program

Diagnostic Microbiology and Infectious Disease

Volumn 30, Issue 2, 1998, Pages 121-129

  Pfaller, Michael A ^a   Jones, Ronald N ^a   Messer, Shawn A ^a   Edmond, Michael B ^b   Wenzel, Richard P ^b  

^a UNIVERSITY OF IOWA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INFECTION CONTROL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; MALE;

EID: 0031939508     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00192-2     Document Type: Article

References (35)

1. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 24:1997;1122-1128.
2. Arevalo MP, Arias A, Andreu A, Rodriguez C, Sierra A. Fluconazole, itraconazole, and ketoconazole in vitro activity against Candida spp. J Chemother. 6:1994;226-229.
3. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson JS, Henderson T, Martone WJ. Secular trends in nosocomial primary blood stream infections in the United States, 1980-1989. Am J Med. 91:(suppl 3B):1991;86S-89S.
4. Bart-Delabesse E, Boiron P, Carolotti A, Dupont B. Candida albicans genotyping studies in patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 31:1993;2933-2937.
5. Cormican MG, Pfaller MA. Standardization of antifungal susceptibility testing. J Antimicrob Chemother. 38:1996;561-578.
6. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy. 40:1994;92-98.
7. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the clinical microbiology laboratory. Clin Microbiol Rev. 6:1993;428-442.
8. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 9:1996;499-511.
9. Graybill JR. Editorial response can we agree on the treatment of candidiasis? Clin Infect Dis. 25:1997;60-62.
10. Martinez-Suarez JV, Rodriguez-Tudela JL. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother. 39:1995;1512-1516.
11. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved Standard M27-A . 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
12. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL. The changing face of candidemia emergence of non-Candida albicans species and antifungal resistance . Am J Med. 100:1996;617-623.
13. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect. 30:(suppl):1995;329-338.
14. Pfaller MA. Epidemiology of fungal infections the promise of molecular typing . Clin Infect Dis. 20:1995;1535-1539.
15. Pfaller MA. Nosocomial candidiasis emerging species, reservoirs, and modes of transmission . Clin Infect Dis. 22:(suppl 2):1996;S89-S94.
16. Pfaller MA, Barry AL. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method. Mycopathologia. 130:1995;3-9.
17. Pfaller MA, Hollis RJ, Sader HS (1992) Chromosomal restriction fragment analysis by pulsed-field gel electrophoresis. In: Clinical Microbiology Procedures Handbook: Supplement 1. Ed, Isenberg HD. Washington, DC: ASM Press. pp. 10.5.c.1-10.6.3.
18. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing Technical advances and potential clinical applications . Clin Infect Dis. 24:1997;776-784.
19. Pfaller MA, Rhine-Chalberg J, Barry AL, Rex JH. Strain variation and antifungal susceptibility among blood stream isolates of Candida species from 21 different medical institutions. Clin Infect Dis. 21:1995;1507-1509.
20. Pfaller MA, Rhine-Chalberg J, Redding SW, Smith J, Farinacci G, Fothergill AW, Rinaldi MG. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 32:1994;59-64.
21. Powderly WG, Robinson K, Keath EJ. Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. AIDS. 6:1992;81-84.
22. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 38:1994;1422-1424.
23. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol. 28:1990;2733-2738.
24. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Evidence of nosocomial spread of Candida albicans causing blood stream infection in a neonatal intensive care unit. Diagn Microbiol Infect Dis. 21:1995;191-194.
25. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother. 39:1995;40-44.
26. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL. Development of interpretive breakpoints for antifungal susceptibility testing conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections . Clin Infect Dis. 24:1997;235-247.
27. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 91:(suppl 3B):1991;72S-75S.
28. Schmid J, Odds FC, Wiselka MJ, Nicholson KJ, Soll DR. Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. J Clin Microbiol. 30:1992;935-941.
29. Sherertz RJ, Gledhill KS, Hampton KD, Pfaller MA, Givner LB, Abramson JS, Dillard RG. Outbreak of Candida blood stream infections associated with retrograde medication administration in a neonatal intensive care unit. J Pediatr. 120:1992;455-461.
30. Voelker R. New group tracks hospital's drug-resistant bugs. J Am Med Assoc. 275:1996;177-178.
31. Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol. 32:1994;975-980.
32. Wardle HM, Law D, Moore CB, Mason C, Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother. 39:1995;868-871.
33. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 20:1995;115-125.
34. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 325:1991;1274-1315.
35. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 37:1993;1847-1849.